Key facts
- This page summarizes Micki Klearman's Form 4 filing for Kezar Life Sciences, Inc. (KZR).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 26 Jul 2023, 17:08.
Micki Klearman - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)
- Reporting relationship
- Director
- Issuer ticker
- KZR
- Reported as of
- 24 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jul 2023, 17:08:02 UTC
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 21 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Belsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Micki Klearman filed Form 4 for Kezar Life Sciences, Inc. (KZR) on 26 Jul 2023.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KZR
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -52,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,000
- Exercise price
- $5.94
- Footnotes
- F1, F2
KZR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +52,000
- Change %
- Price
- Shares after
- 52,000
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,000
- Exercise price
- $2.28
- Footnotes
- F1, F2
KZR
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -26,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,000
- Exercise price
- $5.59
- Footnotes
- F2, F3
KZR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +26,000
- Change %
- Price
- Shares after
- 26,000
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,000
- Exercise price
- $2.28
- Footnotes
- F2, F3
KZR
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -26,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,000
- Exercise price
- $4.80
- Footnotes
- F2, F3
KZR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +26,000
- Change %
- Price
- Shares after
- 26,000
- Date
- 24 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,000
- Exercise price
- $2.28
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of June 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
Footnote F2
On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
Footnote F3
Fully vested and exercisable.